A recent and groundbreaking study has revealed that a daily low dose of aspirin can significantly reduce the risk of colorectal cancer recurrence by approximately 55% in patients with specific PI3K pathway mutations. The ALASCCA trial demonstrated that when aspirin is taken for three years post-surgery, it offers substantial benefits for those with these genetic alterations. Imagine taking a common over-the-counter pill, not just to remedy a headache or treat inflammation, but also to significantly lower the risk of colon cancer recurrence!
The ALASCCA trial, a large and randomized clinical study led by researchers at Karolinska Institutet and Karolinska University Hospital in Sweden, was published in The New England Journal of Medicine. The study analyzed 3,508 patients who had undergone surgery for colon or rectal cancer (stages I-III depending on the site) across 33 hospitals in Sweden, Norway, Denmark, and Finland. All tumors were genetically tested to identify mutations in the PI3K signaling pathway, which includes the PIK3CA, PIK3R1, and PTEN genes. Approximately 37-40% of the patients were found to carry such mutations.
Among those with the mutation, participants were randomized into two groups: one group received 160 mg of aspirin daily, while the other received a placebo. This regimen continued for three years. The results were striking; aspirin significantly reduced recurrence rates compared to those on placebo, showcasing about a 55% reduction in risk.
The PI3K (phosphoinositide 3-kinase) pathway plays a critical role in regulating cell growth and survival. Mutations in this pathway can lead to uncontrolled cell signaling, which cancers exploit to proliferate and resist treatment. The study suggests that by interfering with inflammation and potentially the mutated pathway, aspirin can reduce the chances of surviving cancer cells from regrowing or metastasizing. Notably, this benefit was observed across various factors, including colon versus rectal cancer and different stages of the disease.
This promising outcome primarily targets patients whose tumors exhibit PI3K alterations—roughly a third of those diagnosed with colorectal cancer—and who have had their tumors surgically removed (stage I-III colon or stage II-III rectal cancer). It's essential to note that all participants in the trial were under 80 years old, as those older than this age were not included.
Researchers propose several mechanisms through which aspirin may exert its effects. As an anti-inflammatory drug, aspirin can mitigate inflammation, a known supporter of tumor regrowth. Additionally, it inhibits platelet function, which can protect tiny tumor fragments from the immune system. Tumor cells with genetic mutations in the PI3K pathway appear to be more susceptible to the effects of aspirin, highlighting an example of precision medicine—tailoring treatments to individual genetic profiles.
Despite its benefits, aspirin is not without risks. Some trial participants experienced serious adverse events, including gastrointestinal bleeding and allergic reactions. Aspirin can exacerbate conditions like stomach ulcers and bleeding disorders. There was even one death potentially associated with aspirin use. Consequently, medical professionals stress the importance of using aspirin under medical supervision, carefully weighing the potential risks and benefits for each patient.
Colorectal cancer remains one of the most common cancers globally and is the second leading cause of cancer death in the United States. Approximately two million people worldwide are diagnosed with colorectal cancer each year, and between 20% and 40% of patients develop metastases, making the disease increasingly difficult to treat. Given that there is a risk of recurrence even after successful surgery, reducing this risk is a primary focus of ongoing cancer research.
This new research indicates that a low, daily dose of aspirin could substantially cut the recurrence risk of colorectal cancer by around half for patients with PI3K pathway mutations, three years post-surgery. It suggests a pathway toward personalized cancer treatment, where simple, affordable drugs combined with genetic testing may enhance long-term patient outcomes.
As a result of this study, routine genetic testing for PI3K pathway mutations may soon become standard practice following colorectal cancer surgery, allowing those who test positive to be offered daily low-dose aspirin as part of their adjuvant therapy. Given that aspirin is inexpensive and widely available, this could represent a cost-effective strategy, especially in lower-resource settings. However, further follow-up studies are needed to determine whether these findings also translate into overall survival benefits.
Stay informed and connected with us for more updates on cancer research and treatment advancements.
